Immunotherapy
Feature
CMS proposes coverage of CAR T-cell therapy in trials
A final decision on the proposal is expected by May 2019.
Conference Coverage
Immunotherapy’s cardiac effects require early monitoring, management
Immune checkpoint inhibitors and chimeric antigen receptor T cells can be highly effective against cancer, but can also harm the heart and...
Clinical Review
Targeted Therapy and Immunotherapy in the Treatment of Metastatic Cutaneous Melanoma
Conference Coverage
Novel bispecific CAR shows promise in B-cell malignancies
SAN DIEGO – This is the first in-human study of a bispecific loop CAR in the United States.
Conference Coverage
Uninterrupted ibrutinib with CAR T could improve CLL outcomes
SAN DIEGO – Ibrutinib treatment before and after CAR T-cell therapy in CLL patients may decrease the risk of severe cytokine release syndrome.
Conference Coverage
Armored CAR protects T cells, induces remissions
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1...
Conference Coverage
Long-term side effects of CAR T cells mostly mild
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
From the Journals
Age-related gene expression may affect responses to RCC therapy
Older patients with ccRCC may respond better than younger patients to phosphoinositide 3-kinase (PI3K) or checkpoint inhibition because of age-...
New Therapies
Immunotherapy may hold the key to defeating virally associated cancers
Conference Coverage
ASH preview: Studies target CAR T-cell improvements
New studies highlight the role of CAR T-cell therapies in CLL, ALL, and DLBCL.